trial summary · NCT07605416
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Plasma Cell Leukemia, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patients with plasma cell leukemia. Consolidation therapy is treatment given after initial therapy to kill any cancer cells that may remain in the body. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Carfilzomib inhibits protein complexes called proteasomes, which inhibits cancer cell growth and leads to cancer cell death. Lenalidomide may help kill cancer cells and prevents the growth of blood vessels that cancer cells need to survive. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving teclistamab as consolidation therapy after induction and autologous hematopoietic stem cell transplant may improve survival outcomes in patients with plasma cell leukemia, compared to standard …
Source record: https://clinicaltrials.gov/study/NCT07605416
Facts
| registry id | NCT07605416 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Plasma Cell Leukemia |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 74 |
| start date | 2027-04-20 |
| primary completion | 2032-11-06 |
| completion | 2032-11-06 |
| results posted | not reported |
Conditions
- Plasma Cell Leukemia
Interventions
- Autologous Hematopoietic Stem Cell Transplantation
- Biospecimen Collection
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Carfilzomib
- Computed Tomography
- Daratumumab and Recombinant Human Hyaluronidase
- Dexamethasone
- Fludeoxyglucose F-18
- Lenalidomide
- Magnetic Resonance Imaging
- Melphalan
6 more in the dataset.
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.